New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
07:08 EDTEBSEmergent receives BioThrax orphan drug designation
Emergent BioSolutions that the U.S. Food and Drug Administration has granted orphan drug designation to BioThrax for post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis. This designation provides incentives to the BioThrax PEP Program, including the waiver of the Biologics License Application supplemental regulatory filing fee and marketing exclusivity of up to seven years. Emergent recently announced completion of a non-interference study, results from which will be used to support a supplemental BLA seeking licensure of a PEP indication for BioThrax to be used in combination with antibiotics in people with suspected or confirmed exposure to anthrax spores. This study is fully funded under contract number HHSO100200700037C provided by the Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
16:03 EDTEBSEmergent BioSolutions reports FDA approval of BioThrax
Subscribe for More Information
November 23, 2015
18:01 EDTEBSFDA approves new indication for BioThrax
The U.S. FDA approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine's new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure. BioThrax is manufactured by Emergent BioDefense Operations Lansing, based in Lansing, Michigan. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use